Novavax Inc. (NASDAQ:NVAX) finished Thursday with an addition of $0.66 to close at $9.72, an upside of 7.28 percent. An average of 6,000,780 shares of common stock have been traded in the last five days. There was a fall of -$0.66 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 8,623,475 shares traded, while the 50-day average volume stands at 6,340,136.
NVAX stock has decreased by -42.25% in the last month. The company shares reached their 1-month lowest point of $8.75 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $8.75 and a high of $159.00 in 52 weeks. It has reached a new high 1 time so far this year and lost -93.21% or -$133.35 in price. In spite of this, the price is down -93.89% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
NVAX stock investors should be aware that Novavax Inc. (NVAX) stock had its last reported insider trading activity 274 days ago on Mar 31. In this transaction, the insider spent $919,765. EVP, Chief Legal Officer, Herrmann John A III, disposed of 5,000 shares at a price of $140.91 on Jan 03. The insider now owns more than $704,534 worth of shares. Prior to that, Director YOUNG JAMES F went on to Sale 3,750 shares at $144.16 each on Dec 31. An amount of $540,601 was transacted.
Novavax Inc. (NVAX) stock’s beta is 1.89. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.48.
The quick ratio of Novavax Inc. for the three months ended September 29 was 1.00, and the current ratio was 1.10, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $2.83 billion compared to revenue of $1.15 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Novavax Inc.’s return on assets was -51.30%.
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$168.61 million in the quarter, while revenues were shrunk -91.23%. The analyst consensus anticipated Novavax Inc.’s latest quarter earnings to come in at $1.57 per share, but it turned out to be -$2.15, a -236.90% surprise. For the quarter, EBITDA amounted to -$118.84 million. Shareholders own equity worth $78.5 million.
From a technical analysis perspective, let’s take a brief look at Novavax Inc. (NVAX) price momentum. RSI 9-day as of the close on 29 December was 27.00%, suggesting the stock is oversold, with historical volatility in this time frame at 73.25%.
As of today, NVAX’s price is $9.51 -6.36% or -$0.66 from its 5-day moving average. NVAX is currently trading -41.06% lower than its 20-day SMA and -83.02% lower than its 100-day SMA. However, the stock’s current price level is -47.80% below the SMA50 and -86.49% below the SMA200.
The stochastic %K and %D were 4.64% and 3.18%, respectively, and the average true range (ATR) was 1.36. With the 14-day stochastic at 9.90% and the average true range at 1.51, the RSI (14) stands at 28.51%. The stock has reached -0.77 on the 9-day MACD Oscillator while the 14-day reading was at -2.82.
Jefferies launched coverage on Novavax Inc. (NASDAQ: NVAX) in its analyst report released on December 02, 2022. The firm assigned the stock a Hold rating. The consensus rating for Novavax Inc. (NVAX) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell NVAX, while 1 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is NVAX’s price target for the next 12 months?
Analysts predict a range of price targets between $13.00 and $90.00, with a median target of $55.00. Taking a look at these predictions, the average price target given by analysts for Novavax Inc. (NVAX) stock is $51.80.